Serum vitamin E and oxidative protein modification in hemodialysis: a randomized clinical trial.

Serum vitamin E and oxidative protein modification in hemodialysis: a randomized clinical trial. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Serum vitamin E and oxidative protein modification in hemodialysis: a randomized clinical trial. Abstract Text:

Liang Lu,Penny Erhard,Robert G Salomon,Miriam F Weiss,

BACKGROUND: Patients with end-stage renal disease have increased circulating concentrations of oxidatively modified circulating proteins. Therefore, we examined the ability of vitamin E alpha (alpha-tocopherol) to alter levels of these modified proteins. STUDY DESIGN: Randomized clinical trial. SETTING & PARTICIPANTS: 27 clinically stable patients treated by means of hemodialysis in 4 freestanding outpatient dialysis units. INTERVENTION: Oral administration of 800 IU of vitamin E alpha or placebo daily. OUTCOMES & MEASUREMENTS: Plasma levels of alpha- and gamma-tocopherol and oxidative protein modifications reflecting 2 pathways for protein-oxidant damage. The advanced glycation end product pentosidine reflects glycoxidation. The lipid peroxidation products iso[4]-levuglandin E(2), (E)-4-hydroxy-2-nonenal, and (E)-4-oxo-2-nonenal are formed through covalent adduction. RESULTS: Circulating levels of all oxidative protein modifications were increased in patients with end-stage renal disease. Supplementation with alpha-tocopherol caused alpha-tocopherol levels to rise (13.2 +/- 3.7 to 27.3 +/- 14 mug/mL), but gamma-tocopherol levels to decrease (4.1 +/- 1.6 to 3.5 +/- 1.1 mug/mL). Control values were unchanged. There was no effect on oxidative protein modifications (placebo versus treatment; mean for pentosidine, 15.6 +/- 11.4 (SD): 95% confidence interval (CI), 8.2 to 23.1 versus 21.3 +/- 9.0 pg/mg protein; 95% CI, 16.1 to 26.6; iso[4]-levuglandin E(2), 8.31 +/- 2.55; 95% CI, 6.77 to 9.85 versus 8.46 +/- 2.37 nmol/mL; 95% CI, 7.09 to 9.84; (E)-4-hydroxy-2-nonenal, 0.51 +/- 0.11; 95% CI, 0.45 to 0.57 versus 0.51 +/- 0.08 nmol/mL; 95% CI, 0.46 to 0.56; (E)-4-oxo-2-nonenal, 189 +/- 44; 95% CI, 162 to 215 vs 227 +/- 72 pmol/mL; 95% CI, 183 to 271). LIMITATIONS: Sample size was adequate to show changes in alpha- and gamma-tocopherol levels in response to treatment. However, power was insufficient to show an effect on oxidative protein modifications. CONCLUSIONS: Intervention of oral supplementation with alpha-tocopherol did not result in changes in circulating oxidative protein modifications. A larger study may be required to show an effect in this clinical setting.

Serum vitamin E and oxidative protein modification in hemodialysis: a randomized clinical trial. Publishing Authors By Initials

L Lu,P Erhard,RG Salomon,MF Weiss,

For similar heterocyclic compounds: heterocyclic compounds, 2-ring: benzopyrans: vitamin e research abstracts see: heterocyclic compounds: heterocyclic compounds, 2-ring: benzopyrans: vitamin e research

PUBMED ID PMID:

MEDLINE DATE:

Serum vitamin E and oxidative protein modification in hemodialysis: a randomized clinical trial. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: American journal of kidney diseases : the official

VOLUME: 50

Page Numbers: 305-13

Journal Abbreviation: Am. J. Kidney Dis.

ISSN: 1523-6838

DAY: 3

MONTH: Aug

YEAR: 2007

Serum vitamin E and oxidative protein modification in hemodialysis: a randomized clinical trial. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8110075

Serum vitamin E and oxidative protein modification in hemodialysis: a randomized clinical trial. Keywords Mesh Terms:

KEYWORDS: Vitamin E

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Serum vitamin E and oxidative protein modification in hemodialysis: a randomized clinical trial. Information

Substance Name: Vitamin E

Registry Number: 1406-18-4

Grant and Affiliation Information for Serum vitamin E and oxidative protein modification in hemodialysis: a randomized clinical trial.

AFFILIATION: Department of Chemistry, Case Western Reserve University, Cleveland, OH, USA.

Country: United States

AGENCY: United States NIGMS

GRANT: GM21249

ACRONYM: GM

MEDLINETA: Am J Kidney Dis

REFSOURCE: Am J Kidney Dis. 2007 Nov;50(5):899

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Serum vitamin E and oxidative protein modification in hemodialysis: a randomized clinical trial Related Publications

• A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells.
• Activation of group II metabotropic glutamate receptors attenuates both stress and cue-induced ethanol-seeking and modulates c-fos expression in the hippocampus and amygdala.
• Alcohol and the elderly: an overlooked phenomenon in the literature in developing countries-the Israeli case.
• BMP-2 inhibits proliferation of human aortic smooth muscle cells via p21Cip1/Waf1.
• CD8+ T-cell priming during a central nervous system infection with mouse hepatitis virus.
• Catalytic enantioselective synthesis of adociacetylene B.
• Cis-->trans and trans-->cis isomerizations of styrylcoumarins in the solid state. Importance of the location of free volume in crystal lattices.
• Comparison of photophysical and colloidal properties of biocompatible semiconductor nanocrystals using fluorescence correlation spectroscopy.
• Computational modeling of multicellular constructs with the material point method.
• Depression and quality of life issues in patients with amyotrophic lateral sclerosis.
• Disclosures of illness by doctors to their patients: a qualitative study of doctors with HIV and other serious disorders.
• Hepatocyte antigen as a marker of intestinal metaplasia.
• Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.
• Isolation of a novel platelet-derived growth factor-responsive precursor from the embryonic ventral forebrain.
• New concepts of multiple tests and their use for evaluating high-dimensional EEG data.
• Nonlinear dynamics of paced cardiac cells.
• Pathway analysis of kidney cancer using proteomics and metabolic profiling.
• Pharmacogenomics: challenges and opportunities.
• Role of the replicase gene of murine coronavirus JHM strain in hepatitis.
• Scoliosis: a journal dedicated to multidisciplinary research on prevention, control, and treatment of scoliosis and other spinal deformities.
• Seeking safety therapy for adolescent girls with PTSD and substance use disorder: a randomized controlled trial.
• Shot-noise limited single-molecule FRET histograms: comparison between theory and experiments.
• Src-like adaptor protein (SLAP) regulates B cell receptor levels in a c-Cbl-dependent manner.
• Stoichiometry of a pore mutation that abolishes picrotoxin-mediated antagonism of the GABAA receptor.
• System for expression of microsporidian methionine amino peptidase type 2 (MetAP2) in the yeast Saccharomyces cerevisiae.
• The transmission of bluetongue virus by embryo transfer in sheep.
• Transplantation of multipotent astrocytic stem cells into a rat model of neonatal hypoxic-ischemic encephalopathy.
• Vulnerable window for conduction block in a one-dimensional cable of cardiac cells, 1: single extrasystoles.
• Vulnerable window for conduction block in a one-dimensional cable of cardiac cells, 2: multiple extrasystoles.
• Why do we treat adolescent idiopathic scoliosis? What we want to obtain and to avoid for our patients. SOSORT 2005 Consensus paper.